Background
Findings
Methods
(Anti)rheumatic therapies and care
Diagnoses and therapy of psychological morbidities
Statistical analysis
Results
Variable | JIA | |||
---|---|---|---|---|
total | 12-14 years | 15-17 years | 18-20 years | |
(n=628) | (n=182) | (n=234) | (n=212) | |
Sociodemographic data | ||||
Age, years, mean (SD) | 16.1 (2.5) | 13.0 (0.8) | 15.9 (0.8) | 19.0 (0.9) |
Female, no. (%) | 446 (71) | 130 (71) | 160 (68) | 156 (74) |
JIA category, no. (%) | ||||
Polyarthritis, adult type | 97 (15) | 21 (11) | 26 (11) | 50 (24) |
Polyarthritis, RF-negative | 195 (31) | 68 (37) | 71 (30) | 56 (26) |
Systemic JIA | 67 (11) | 16 (8.8) | 29 (12) | 22 (10) |
Oligoarthritis | 94 (15) | 37 (20) | 36 (15) | 21 (9.9) |
Psoriatic arthritis | 21 (3) | 5 (2.7) | 8 (3.4) | 8 (3.8) |
Enthesitis-related arthritis/juvenile spondyloarthritis | 57 (9) | 8 (4.4) | 29 (12) | 20 (9.4) |
Other JIA | 97 (15) | 27 (15) | 35 (15) | 35 (16) |
Antirheumatic therapy, no. (%) | ||||
Any b/cs/tsDMARD | 554 (88) | 165 (91) | 197 (84) | 192 (91) |
Any bDMARD | 371 (59) | 99 (54) | 129 (55) | 143 (67) |
Any csDMARD | 321 (51) | 111 (61) | 122 (52) | 88 (41) |
Any tsDMARD | 9 (1.4) | 3 (1.6) | 4 (1.7) | 2 (0.9) |
Any NSAID | 294 (47) | 79 (43) | 118 (50) | 97 (46) |
Systemic GCs | 190 (30) | 41 (22) | 79 (34) | 70 (33) |
GCs monotherapy | 74 (12) | 17 (9) | 37 (16) | 20 (9.4) |
Rheumatology care, no (%) | ||||
Total | 416 (66) | 119 (65) | 142 (61) | 155 (73) |
Pediatric | 297 (47) | 118 (65) | 133 (57) | 46 (22) |
Adult | 172 (27) | 8 (4.4) | 30 (13) | 134 (63) |
Psychological disorders and related drug prescription
Variable | JIA | Controls | |||
---|---|---|---|---|---|
Total (n=628) | any psychological disorders | no psychological disorders | any psychological disorders | no psychological disorders | |
(n=96) | (n=532) | (n=513) | (n=5,757) | ||
Sociodemographic data | |||||
Age, years, mean (SD) | 16.1 (2.5) | 16.3 (2.6) | 16.1 (2.5) | 16.5 (2.5) | 16.1 (2.5) |
Female, no. (%) | 446 (71) | 74 (77.1) | 372 (69.9) | 414 (81) | 4046 (70) |
JIA category, no. (%) | |||||
Polyarthritis, adult type | 97 (15) | 12 (12) | 85 (16) | - | - |
Polyarthritis, RF-negative | 195 (31) | 24 (25) | 171 (32) | - | - |
Systemic JIA | 67 (11) | 8 (8.3) | 59 (11) | - | - |
Oligoarthritis | 94 (15) | 19 (20) | 75 (14) | - | - |
Psoriatic arthritis | 21 (3.3) | 4 (4.2) | 17 (3.2) | - | - |
Enthesitis-related arthritis/juvenile spondyloarthritis | 57 (9.1) | 13 (13) | 44 (8.3) | - | - |
Other juvenile arthritis | 97 (15) | 16 (16) | 81 (15) | - | - |
Antirheumatic therapy, no. (%) | |||||
Any bDMARD | 371 (59) | 62 (65) | 309 (58) | 1 (0.2) | 6 (0.1) |
Any csDMARD | 321 (51) | 45 (47) | 276 (52) | 1 (0.2) | 1 (0.0) |
Any tsDMARD | 9 (1.4) | 0 (0) | 9 (1.9) | 1 (0.2) | 0 (0.0) |
Any NSAID | 294 (47) | 55 (57) | 239 (45) | 92 (18) | 712 (12) |
Systemic GCs | 190 (30) | 36 (37) | 154 (29) | 12 (2.3) | 111 (1.9) |
GCs monotherapy | 74 (11.8) | 10 (10) | 64 (12) | 12 (2.3) | 110 (1.9) |
Therapy related to psych. disorder, no. (%) | |||||
Psycholeptics (N05) | 9 (1.4) | 5 (5.2) | 4 (0.8) | 36 (7.0) | 33 (0.6) |
Antipsychotics (N05A) | 2 (0.3) | 2 (2.1) | 0 (0) | 28 (5.5) | 20 (0.3) |
Anxiolytics (N05B) | 0 (0) | 0 (0) | 0 (0) | 4 (0.8) | 9 (0.2) |
Sedatives (N05C) | 7 (1.1) | 3 (3.1) | 4 (0.8) | 16 (3.1) | 6 (0.1) |
Homeopathic psycholeptics (N05H) | 0 (0) | 0 (0) | 1 (0.2) | 0 (0.0) | |
Psychoanaleptics (N06) | 40 (6.4) | 24 (25) | 16 (3.0) | 140 (27) | 118 (2.0) |
Antidepressants (N06A) | 25 (3.9) | 20 (21) | 5 (0.9) | 106 (21) | 40 (0.7) |
Non-selective monoamine reuptake inhibitors (N06AA) | 9 (1.4) | 6 (6.3) | 3 (0.5) | 14 (2.7) | 16 (0.3) |
Selective serotonin reuptake inhibitors (N06AB) | 15 (2.4) | 13 (13) | 2 (0.2) | 83 (16) | 18 (0.3) |
Pediatric psychotherapy | 71 (11) | 49 (51) | 22 (4.1) | 241 (47) | 96 (1.7) |
Pediatric psychiatry | 37 (5.9) | 18 (19) | 19 (3.6) | 158 (31) | 160 (2.8) |
Drugs (N05/N06) or psychotherapy | 105 (17) | 65 (68) | 40 (7.5) | 331 (64) | 220 (3.8) |